Hepatocellular Carcinoma Treatment and Prognosis
Hepatocellular Carcinoma Treatment and Prognosis is a research topic within Hepatology. Science Explorer counts 57k research works in it since 1950. 16.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the management, diagnosis, and treatment of hepatocellular carcinoma (HCC), also known as liver cancer. It covers various aspects including clinical practice guidelines, radiofrequency ablation, use of sorafenib, liver resection, and survival rates.
- Hepatocellular Carcinoma
- Liver Cancer
- Management
- Treatment
- Diagnosis
- Radiofrequency Ablation
- Sorafenib
- Clinical Practice Guidelines
- Liver Resection
- Survival
- Research works
- 57k fractional, since 1950
- In the world top 10%
- 9.1k per year above
- Top-10% rate
- 16.1% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +28% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Hepatocellular Carcinoma Treatment and Prognosis research?
By volume, China and the United States publish the most (3.8k and 2.1k works in 2022–2025).
By volume, 2022–2025
- 1 China 3.8k works
- 2 United States 2.1k works
- 3 Japan 996 works
- 4 Italy 535 works
- 5 South Korea 529 works
- 6 Germany 434 works
- 7 India 355 works
- 8 France 339 works
- 9 United Kingdom 278 works
- 10 Taiwan 222 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Hepatocellular Carcinoma Treatment and Prognosis research?
By volume in 2022–2025, Sun Yat-sen University publishes the most Hepatocellular Carcinoma Treatment and Prognosis research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and The University of Texas MD Anderson Cancer Center.
By volume, 2022–2025
- 1 Sun Yat-sen UniversityChina 130 works
- 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 84 works
- 3 The University of Texas MD Anderson Cancer CenterUnited States 76 works
- 4 Sichuan UniversityChina 63 works
- 5 Memorial Sloan Kettering Cancer CenterUnited States 58 works
- 6 Chinese PLA General HospitalChina 55 works
- 7 Fudan UniversityChina 54 works
- 8 Guangxi Medical UniversityChina 54 works
- 9 West China Hospital of Sichuan UniversityChina 50 works
- 10 The First Affiliated Hospital, Sun Yat-sen UniversityChina 48 works
Who are the leading researchers in Hepatocellular Carcinoma Treatment and Prognosis?
The most-cited researchers publishing on Hepatocellular Carcinoma Treatment and Prognosis include Lawrence H. Schwartz, Daniel J. Sargent and Jordi Bruix.
- 1 Lawrence H. Schwartz United States 5.8k citations
- 2 Daniel J. Sargent United States 4.1k citations
- 3 Jordi Bruix Spain 3.7k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Hepatocellular Carcinoma Treatment and Prognosis research done?
The largest centres of Hepatocellular Carcinoma Treatment and Prognosis research in 2022–2025 are Beijing (China), Guangzhou (China), Shanghai (China) and Seoul (South Korea). Among places with at least 20 works in it, it is an unusually large share of all research in Rozzano and Villejuif.
Largest cities, 2022–2025
Where it is the local speciality
- RozzanoIT · 34.4 works20×
- VillejuifFR · 21.3 works15×
Location quotient: how much more of its research is in Hepatocellular Carcinoma Treatment and Prognosis than the world average.
Where is the best place to study Hepatocellular Carcinoma Treatment and Prognosis?
Among universities, judged by research, Humanitas University, Sun Yat-sen University and Fujian Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Humanitas UniversityItaly | 66.5 | 20.2% | 20.5× | 18 | +252.0% |
| 2 | Sun Yat-sen UniversityChina | 60.7 | 18.6% | 7.2× | 130 | +52.5% |
| 3 | Fujian Medical UniversityChina | 59.3 | 19.6% | 11.2× | 44 | +38.7% |
| 4 | Second Military Medical UniversityChina | 58.2 | 22.3% | 32.2× | 42 | -17.2% |
| 5 | Shanghai Medical College of Fudan UniversityChina | 57.9 | 25.5% | 10.6× | 10 | +96.4% |
| 6 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 56.4 | 16.6% | 7.7× | 84 | +45.8% |
| 7 | Kindai UniversityJapan | 55.1 | 28.3% | 9.0× | 17 | -1.4% |
| 8 | Guangxi Medical UniversityChina | 54.9 | 16.4% | 28.3× | 54 | -7.5% |
| 9 | Shandong First Medical UniversityChina | 54.8 | 17.6% | 11.2× | 32 | +29.2% |
| 10 | Nara Medical UniversityJapan | 54.7 | 14.8% | 14.7× | 11 | +205.2% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Hepatocellular Carcinoma Treatment and Prognosis research growing?
Output in 2018–2022 was 28% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Hepatocellular Carcinoma Treatment and Prognosis.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.